Comparing NewLink Genetics Corporation (NLNK) & Its Rivals

NewLink Genetics Corporation (NASDAQ: NLNK) is one of 194 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its peers? We will compare NewLink Genetics Corporation to similar businesses based on the strength of its earnings, dividends, analyst recommendations, valuation, risk, institutional ownership and profitability.

Institutional and Insider Ownership

45.3% of NewLink Genetics Corporation shares are owned by institutional investors. Comparatively, 48.7% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 13.7% of NewLink Genetics Corporation shares are owned by insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and price targets for NewLink Genetics Corporation and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NewLink Genetics Corporation 0 0 6 0 3.00
NewLink Genetics Corporation Competitors 499 2373 6467 121 2.66

NewLink Genetics Corporation currently has a consensus target price of $25.67, indicating a potential upside of 184.55%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 17.71%. Given NewLink Genetics Corporation’s stronger consensus rating and higher probable upside, equities analysts plainly believe NewLink Genetics Corporation is more favorable than its peers.


This table compares NewLink Genetics Corporation and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NewLink Genetics Corporation -229.19% -63.39% -47.83%
NewLink Genetics Corporation Competitors -3,815.02% -115.40% -39.36%

Valuation & Earnings

This table compares NewLink Genetics Corporation and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
NewLink Genetics Corporation $35.77 million -$85.15 million -3.70
NewLink Genetics Corporation Competitors $220.75 million -$39.68 million -77.03

NewLink Genetics Corporation’s peers have higher revenue and earnings than NewLink Genetics Corporation. NewLink Genetics Corporation is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

NewLink Genetics Corporation has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Comparatively, NewLink Genetics Corporation’s peers have a beta of 1.49, meaning that their average share price is 49% more volatile than the S&P 500.


NewLink Genetics Corporation peers beat NewLink Genetics Corporation on 7 of the 12 factors compared.

NewLink Genetics Corporation Company Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with's FREE daily email newsletter.

Leave a Reply